I. What is 3D Bio-printing?

As a branch of regenerative medicine, 3D bio-printing has transformed from a futuristic technology that “seems very cool” to a tangible technology that we can see with our own eyes.

This technology uses the three-dimensional model as the “blueprint” and 3D printer and bio materials to produce customized grafts, auxilliary grafts, scaffolds, tissues and organs, and other products from the biological ink containing cells and biological materials, so as to realize the tissue functionalization.

Similar to the mechanism of 3D printing, 3D bio- printing builds a three-dimensional object by stacking layers of materials one at a time. Unlike ordinary 3D printers, which use metal, plastic or ceramic materials, 3D bioprinter uses “bio-ink” “: A printable material containing living cells. Many biological inks comprise of water-ruch molecule called “hydrogel”. The hydrogel is mixed with millions of living cells and various chemicals and is used to promote cell communication and growth. Some biological inks only contain single cells, and some combine many different cells to create more complex biological functional structures.

Generally speaking, 3D bioprinting means to print biocompatible materials containing living cells into three-dimensional functional living tissues through 3D printing technology, and realize functions similar to, identical with, or even superior to target tissues or biological organs.

It is fair to say that 3D biological printing is one of the most promising emerging technologies for manufacturing human organs in vitro.

II. Prospect of 3D Bioprinting Technology

Since the development of the first bioprinter at the beginning of the 21st century, bioprinting has entered many fields including pathological model production, tissue design for drug screening, medical research and regenerative medicine.

When 3D bioprinting technology was first applied in biomedicine, only 3D scaffolds including bone, cartilage, blood vessels, nerves, tendons, teeth and skin tissues could be printed. Nowadays, its application has gradually expanded to producing organ prototypes with more complex structures and biological components, such as liver, kidney and heart. Up to now, 3D biological printing technology has gradually matured in scientific research and application fields, including:

• Biomimetic tissues and organs: such as spinal cord, heart, skin printing, etc;
• Tissue engineering scaffold: such as bone repair scaffold, meniscus scaffold, bone cartilage scaffold, etc;
• Cell research and treatment: such as cell immune research, embryonic stem cell printing, neural cell printing, etc;
• Personalized drug testing model: such as organ chip, personalized liver cancer model, brain like model for neurodrug screening;
• High end medical devices: such as anti HPV protein sustained release stent, heart stent, vascular stent, artificial heart valve, etc;
• Development and application of advanced materials: such as artificial meat.

If we compare human body to a intricate machine, the ultimate role of 3D bioprinting is similar to the technologies that people use to manufacture “spare parts” that can replace the “faulty parts” of this “machine” (organ transplantation). However, at the current stage, it can only be used to make some simulation models (in vitro models) used to simulate the process of “locating fault parts”. To be more exact, we still have a long way to go before realizing the its ultimate purpose of “faulty parts replacement” with the clinical replacement of patients’ functional organs as its end point.

Despite still in its initial stage, this technology is expected to bring about disrumptive changes to the healthcare and pharmaceutical industries: all major market analysis and prediction institutions around the world have seen the considerable market potential of 3D bioprinting technology, and have made their own 5- to 10-year market estimation of this technology.

Conservative estimation shows that, within next 10 years, this technology will have a global TAM of more than US $2 billion. North America currently has the largest market share by region and its advantage will remain for the following 5-10 years. However, the Asia-Pacific region will have a higher growth rate in the next 5 years, and will be one of the main markets for biological 3D printing in the future.

III. The Key and Major Obstacles to the Development of 3D Bioprinting Technology

At present, the research of 3D bioprinting technology in the field of tissue engineering is still in its infancy. How to use 3D printing technology to construct living tissue structure is still a difficult task. Therefore, successful 3D bioprinting must overcome the following specific technical problems.

1. Cell Technology

What kind of cells to choose is crucial for the biological tissues or organs produced by 3D bioprinting. Different tissues of the human body are composed of unique cells. The liver mainly contains liver cells, the heart mainly contains myocardial cells, and the skin mainly contains various epithelial cells. However, not all tissue-specific cells can be isolated and cultured in vitro, and not all cells can maintain their biological activity after being exposed to the 3D bioprinting environment. Therefore, how to optimize cell idolation, culture and proliferation technology is the precondition to ensure the success of 3D biological printing.

2. Biomaterials (aka. Bio ink)

The “biomaterial (bio ink)” required for printing is one of the most important factors that affect and restrict the development of 3D biological printing. Different tissues and organs of the human body have their own physical and mechanical characteristics. The softness of skin tissue and the hardness of bone tissue lead to the need to select biomaterials corresponding to tissue characteristics during 3D printing of different tissues, and these materials need to maintain the biological activity and function of selected cells to the greatest extent. More importantly, the selected materials must be able to be operated through a 3D printing system. This makes the selection of biomaterials very challenging, and requires continuous optimization and improvement in the printing process. On the other hand, high-quality and suitable materials are often difficult to obtain and extremely expensive, which will be another major problem to overcome in the process of technological development. Therefore, biological 3D printing still has many technical problems that need to be addressed, and requires multidisciplinary and interdisciplinary cooperation.

3. Manufacture Platforms

Currently, the main platforms used for 3D bioprinting falls in the following three categories: Laser-based, Inkjet-based, and Extrusion-based. The three platforms have their own advantages and disadvantages, different special functions and requirements for hardware technology. How to make different tissues and organs accordingly and how to reasonably choose the platform are also the key to the success of 3D bioprinting. These three platforms have been used in traditional printing or 3D manufacturing systems, and the critical point is how to integrate them into the biological manufacturing system, so that they can play the maximum role, while maintaining the biological activity of cells and the physical properties of biological materials, and making products meet the standards of medical applications, which must be overcome and constantly optimized.

4. Vein System

Another important point is that most human tissues and organs have their own vascular systems and need to get enough blood supply to maintain bioactivities. However, the current 3D bioprinting technology is not yet able to produce substitutes that have the same functions as the human vascular system, let alone integrating the vascular system into 3D printed tissues. Without the vascular system, the 3D printed organs will not be able to survive for a long time, and our aspiration of using 3D printed organs to rescue patients with organ failure will be just a fantasy. Therefore, 3D bioprinting of tissues and organs with vascular system that enables them to integrate into the whole blood circulation system of the human body is the biggest challenge and the ultimate goal of this industry.

IV. “In Situ Bioprinting” As The More Advanced Clinical Application of 3D Biopriting

Nowadays, the grafts are printed in vitro before transplantation. However, a more advanced application of 3D bioprinting technology that will revolutionaize the current clinical practice is to realize tissue repair and organ replacement in vivo. To achieve this, we need to be aware of shortcomings of the existing bioprinting technology:

• It is difficult for the current technology to achieve the irregular shape required for actual clinical tissue repair, and the printed matter is easy to degrade and deform after in vitro cultivation;
• The existing bioprinting hydrogel materials are difficult to sew and fit, and need chemical modification to be well bonded, and chemical modification and adhesive will also significantly reduce the regeneration effect;
• The printing process is complex and slow (usually several hours), which not only leads to slow response to traumatic time and reduces the regeneration effect, but also patients often need a second operation;
• The printing process is complex and slow (usually several hours), which not only leads to slow response to traumatic time and reduces the regeneration effect, but also patients often need a second operation;

To conquer the abovementioned challenges, researchers have developped a biological printing method that has recently attracted wide attention: directly printing bio ink into the patient’s body, namely “in situ biological printing”, also known as “in vivo bioprinting”.

Compared with in vitro bioprinting, in situ bioprinting has the following advantages:

• Doctors can conduct treatment and control the process in real time, and ensure that the printed matter can be accurately matched with the injury;
• In situ crosslinking can effectively improve the combination degree of prints and residual tissues;
• Compared with in vitro culture, human body can provide better conditions for cell regeneration and infection reduction;
• In addition, the flexibility of in situ printing is very high. Even if there is no professional 3D bioprinter, in some emergencies (battlefield, traffic accidents, etc.), manual operation or direct injection of biological ink can also be used as an alternative.

The “tissue repair robot” jointly built by RunYoung and the godfather of surgical robotics is exactly aiming at in situ bioprinting technology. Through the development of minimally invasive robotic surgery system, 3D tissue printing will be realized within the human body.

Through the cooperation with the godfather of surgical robotics and with the leading innovation experts in biomaterial research, the product has applied for patent in USA and its prototype has been successfully manufactured. It is expected that in situ bioprinting in small animal models will happen in 2022-23, and in situ bioprinting in large animal models will take place in 2024-25.

With the increasingly vigorous development of 3D bioprinting technology, more biomedical applications are expected to arise in the next few years. RunYoung will be committed to working with industrial partners, universities and research institutes to create a path for disruptive and innovative breakthroughs in the field of 3D bioprinting, and turn 3D bioprinting into a tangible future by pushing its wide application in clinical practice!

The post <strong>Positioning “Tissue Repair Robotics” Project as A Key Part of Its Key Strategic Layout, RunYoung Sets Its Target In This Field!</strong> appeared first on RunYoung.

Recently, Mr. Lu Qiqi, General Manager of RunYoung Capital Management Co., Ltd., led a team to Israel for investigation and exchange. During the visit, a number of China-Israel cooperation projects have been confirmed, and the long-awaited surgical robot platform project has officially been launched. At present, the equity structure of the project has been finalized, and the parties have officially signed a cooperation agreement.

This jointly developed original surgical robot platform was led by Professor Moshe Shoham, who was dubbed as the “godfather of surgical robotics” by the industry. Professor Shoham presides the research and development of this project, whose first application direction aims at tissue repair surgery.

Meanwhile, Ori Hadomi, former CEO of Mazor Robotics, will also join this project assuming the role of Chairman of its Board. He will give full play to his experience in the commercialization and launching of surgical robotic projects, spares no effort to introduce surgical robot products with immense clinical application potential to the Chinese market, and comprehensively promote the introduction and launching of related technologies.

Professor Shoham and Mr. Hadomi are highly regarded authorities, at the technical and commercial levels respectively, in the field of medical robotics. As an academician of the US National Academy of Engineering, Professor Shoham has successively founded several top surgical robotic companies, including Microbot Medical (subversive intravascular microsurgery robots), Tamar Robotics (micro neurosurgery robots) and ForSight Robtics (microsurgery robots). Every product developed by Professor Shoham has attracted worldwide attention for its disruptiveness. Mr. Hadomi, on the other hand, has a blazing trail of entrepreneurial experience in medical robots. Under his leadership, Mazor Robotics developed from a concept company to a global leader in the market of spine surgery robot, and was listed on NASDAQ and eventually acquired by Medtronic.

It is worth mentioning that the two had created a legend by “perfectly combining technology with business” at Mazor. This time, with the help of RunYoung Capital, this golden pair has joined hands again to develop a new series of surgical robot products that, for the first time, is tailored for the Chinese market. This is a full-stage cooperation that covers clinical needs analysis, technical difficulties research, original research and development, and new product introduction. Therefore, the signing of the contract is undoubtedly an exciting starting point.

RunYoung will gradually unveil more details about this cooperation as our key project in 2023. Please stay tuned!

The post <strong>RunYoung News|RunYoung Joins Hands with Surgical Robotics Pioneer to Create An Original Surgical Robotic Platform That Caters To China’s Unmet Clinical Needs</strong> appeared first on RunYoung.

On March 22nd, the latest ” Report on the Most Active Venture Capital Funds in Israel 2020″ was released. RunYoung Investment was honored to be on the list. The report ranks Israeli and foreign venture capital funds based on the number of first-time investment deals (the first time a venture capital fund added a company to its portfolio) in Israeli high-tech companies in the past year. With five successful investments in Israeli startups in a single year, RunYoung Investment tied for ninth place on the list and was the only Chinese venture capital fund listed.

The annual publication: “Report on Israel’s Most Active Venture Capital Funds” is co-produced by the IVC Research Center (Israel’s leading online data provider of data and analysis on Israel’s high-tech, venture capital and private equity industries) and APM & Co (one of Israel’s most prominent law firms in the high-tech venture capital sector). First launched in 2012, the report is based on the number of first-time investments in Israeli high-tech companies by global venture capital funds. It provides an annual research, rating and ranking of the most active venture capital funds as well as trend insights. It is the most authoritative annual report in the field.

The latest edition of the 2020 Annual Report summarizes three major trends in venture capital investments directed at Israeli high-tech companies:

1. The COVID-19 epidemic has accelerated the activity of capital investments in Israeli high-tech companies. Even in the face of the challenges of the COVID-19 pandemic, global venture capital funds added 620 new high-tech companies from Israel to their portfolios in 2020. This is the highest level in nearly seven years and is up from 579 in 2018 (second highest ever) and 536 in 2017 (third highest ever), according to the report. This growth reflects the enthusiasm of investors betting on high-tech projects in the healthcare industry and its derivative segments amidst the COVID-19 epidemic.
2. Israeli technology companies have continued to be closely watched and competed for by foreign VCs in recent years. According to the findings of the IVC Research Center, of the 620 first-time investments directed to Israeli high-tech companies in 2020, 281 came from Israeli-based VCs and another 339 investments (55%) came from foreign VC funds, with an average of 1.6 companies per foreign VC fund. The report shows that the proportion of investments from foreign VCs has remained stable at around 60% since 2014, fully demonstrating the attractiveness of Israeli technology companies and the competition for outstanding Israeli startups by foreign capital.
3. There is a growing enthusiasm for capital investment in mid-to-late-stage Israeli high-tech projects. According to IVC, the majority of first investments in 2020 (65%) are in early-stage investments (seed and Series A), with another 25% in mid-stage financing and 10% in late-stage financing. In contrast, capital investment in the next round (mid- and late-stage) of projects is on the rise. The data shows that the number of first-time investments in late-stage projects has grown by about 119% since 2014, representing 10% of total initial investments in 2020. Marianna Shapira, Research Manager at IVC, said, “The number of Israeli venture capital funds will grow in 2020. At the same time, we are seeing the emergence of new types of investment capital, such as growth funds and academic funds, which are meeting the various needs of startups.” In fact, in this report, RunYoung Investment is listed as a representative of an “academic fund” because most of its investments are in early-stage academic research projects in Israel.

The post News | RunYoung Investment Named to the “2020 List of Most Active Venture Capital Funds in Israel” appeared first on RunYoung.

About Professor Aaron Ciechanover: Professor Aaron Ciechanover is a well-known Israeli biochemist who was awarded the Nobel Prize in Chemistry in 2004 for his discovery of ubiquitin-regulated protein degradation. He was also elected as a foreign academician of the US National Academy of Sciences, a foreign academician of the US National Academy of Medicine, a foreign academician of the US Academy of Arts and Sciences, an academician of the Israel Academy of Humanities and Natural Sciences, a foreign academician of the Chinese Academy of Sciences, and an honorary professor of the Chinese Academy of Medical Sciences. Professor Ciechanover has profound knowledge in basic biochemistry research and has been working on clinical applications of basic research resulting in significant contributions to translational medicine research. Professor Ciechanover has a deep friendship with China and has long been interested in the development of scientific research in China. He has visited China more than one hundred and fifty times and established close cooperation with multiple Chinese scientists. Professor Ciechanover has served as a visiting professor and advisor to several institutions in China and has worked with Chinese research institutions to train students as he continually contributes to education and research in China.

About the Cancer Hospital of Medical Sciences: The experts from the Cancer Hospital of Medical Sciences that participated in the dialogue cover the diagnosis and treatment of several major solid tumors including digestive system oncology, urological system oncology, respiratory system oncology and breast cancer. Their multidisciplinary comprehensive treatment (MDT) team of digestive tract oncology is the leader in China in the fields of liver cancer, colorectal cancer liver metastasis and neuroendocrine tumors. The team has had success with 46.4% of patients with liver metastases from colorectal cancer and 68% of patients with liver cancer having a five-year survival rate after surgery which is comparable advanced international levels. In addition, the team is also affiliated with the Key Laboratory of Gastrointestinal Oncology Drug Gene Editing Screening and R&D of the Chinese Academy of Medical Sciences. This affiliation has produced numerous basic and clinical studies and is a force in translational medicine. The purpose of the online interaction was to promote the exchange and cooperation between two top teams in China and abroad.

During the online discussion, Professor Ciechanover introduced his research experience and the specifics about training for a Doctor of Medicine (M.D.) and a Doctor of Science (PH.D.) in Israel. In addition, he summarized the research and clinical overview of the School of Medicine of the Technion-Israel Institute of Technology and the research progress and results of his group. Finally, he praised China for its success in fighting epidemics. Soon after, Ruth Perets of Rambam Hospital, the largest hospital in northern Israel, presented the process and specifications for Phase I clinical studies in Israel. Next, Professor Hong Zhao, Deputy Director of Hepatobiliary Surgery, Professor Yuchen Jiao, Key Laboratory and Professor Aiping Zhou, Deputy Director of Internal Medicine of the team of the Cancer Hospital of Chinese Academy of Medical Sciences, gave an overview and latest progress of their work in clinical treatment, basic research and clinical research. Professor Ciechanover spoke highly of the achievements of his Chinese counterparts, repeatedly saying that they exceeded expectations and expressed his intention to cooperate further. In a follow-up closed-door discussion, Professor Ciechanover presented his further research based on the Nobel Prize winning work, demonstrating a mechanism, preliminary drug design and results of cytological zoological experiments with possible application to anti-cancer therapy. The two sides had a lively discussion on the potential mechanism and how to formulate the drug for solid tumor treatment. Both sides affirmed their desire to begin cooperation and the exchange well received by all.

Professors Hong Zhao, Aiping Zhou and Yuchen Jiao share an overview of their team’s work and latest progress

Other participants in the discussion included experts from Cancer Hospital of Chinese Academy of Medical Sciences, such as Professor Jianzhong Shou, Deputy Director of Urology Department, Professor Fei Ma, Deputy Director of Internal Medicine Department, Professor Yu Tang, Director of GCP Office and Professor Xingang Bi of the Urology Department. 

This discussion panel was organized by RunYoung Investment and Healthcare Drinks. As an emerging investment team, RunYoung Investment focuses generally on leading-edge basic academic research and to obtain technology patents and introduce them into China to help propel China’s innovative scientific research forward. RunYoung has been following Professor Ciechanover’s projects and facilitated this exchange following its investment in hopes that the effort will lead to accelerated landing of the advanced technologies to China.

With the capital and resources needed to promote the development of China’s medical technology, RunYoung Investment will organize monthly dialogues with Healthcare Drinks to open a window of communication between domestic and foreign research professors, provide opportunities for cooperation within the industry, explore the best path of technology transformation, and promote the bright future of China’s medical technology industry. We will continue to focus on innovative technologies around the world and look forward to more partners joining us in our journey.

The post Top-level Links Between Research and Practice of Translational Medicine: Dialogue Between Experts from the Cancer Hospital of the Academy of Medical Sciences and Professor Aaron Ciechanover, Nobel Laureate in Chemistry appeared first on RunYoung.

The Israel Prize is Israel’s annual national award and is regarded as the country’s highest award. It is given to those who have distinguished themselves in their respective fields or who have made significant contributions to the nation of Israel. Usually, the President of Israel, the Prime Minister, the Speaker of the Knesset and the President of the Supreme Court attend the award ceremony.

Professor Eli Keshet is a pioneer in the field of vascular endothelial growth factor VEGF research. He also discovered the cause of neonatal jaundice, laying the groundwork for finding a revolutionary clinical solution that will benefit millions of newborn children. As early as 1992, Prof. Keshet published an article in Nature demonstrating that hypoxia-inducible factor (HIF) is an important regulator of VEGF. He made an outstanding contribution to the use of VEGF as a target and a drug by thoroughly investigating the role of VEGF in disease. Prof. Keshet’s team has published more than 180 articles with more than 30,000 total citations and several high impact factor papers in top academic journals such as Nature, Cell, Nature Medicine, PNAS, and Cell Metabolism. For his pioneering contributions to VEGF research and regulation of angiogenesis, Professor Eli Keshet previously received two prestigious industry awards: the 2006 EMET Life Sciences Excellence Award in Israel and the 2015 NAVBO Piaget-Bendit Award in the US.

VEGF research has made “delayed aging” and “healthy aging” no longer a dream

Perhaps you are wondering what VEGF is? Vascular endothelial growth factor (VEGF) is the most important pro-angiogenic factor that induces neovascularization in vivo. With continuous research, it has been found that VEGF mainly has the following functions: (1) immunosuppression (2) promotion of wound healing (3) neuroprotection (4) promotion of blood vessel formation in tumors, and (5) maintenance of the stability of the internal bone environment. In the past 30 years, research on VEGF has exploded, and as of December 13, 2020, there were 81,969 articles in PubMed with VEGF as the keyword and 794 VEGF-related studies were registered on Clinicaltrials.gov. As a leading expert in the field of VEFG research, Prof. Keshet’s lab is currently conducting a study on the application of VEGF to “healthy aging” with the support of RunYoung’s team and has already made breakthroughs.

Life is a process of development, maturation, and then gradual aging, and aging is the natural law of human development. As living standards improve and as life expectancy increases, individuals are in poor health for longer periods of time and aging-related diseases and poor health are a major social burden.

Current strategies to prevent aging suboptimal health and disease are focused on specific aging-related processes, including metabolic intervention through a healthy diet, delaying cellular aging through senolytic drugs, and seeking to increase the number of stem cells to improve their ability to regenerate and differentiate. In fact, vascular aging is one of the most neglected aging processes in humans. Professor Keshet’s research has demonstrated that modulation of vascular growth factor signaling can achieve a delay in the aging process of the vascular system.

The research by Professor Keshet and his team has been validated in mouse models. By slightly increasing the circulating levels of VEGF, mice treated with VEGF maintained a “youthful” metabolic profile and metabolic flexibility in old age, significant reductions in age-induced fatty liver (steatosis) and hepatocyte damage, and improvement in osteoporosis conditions. Next, with the financial support of the RunYoung Investment, Professor Keshet and his experimental team will focus on the study of vascular growth factor dosing and drug-forming properties.

Yigong Shi’s appeal, which is being followed by RunYoung

“Our universities could be stronger in basic research transformation, not for lack of transformation capabilities, but because we don’t have the basic research to transform!” Some time ago, an appeal from Professor Yigong Shi, president of Westlake University, pointed out that the lack of basic research capability in China’s universities is the biggest crisis lurking in China.

A group of scholars like Prof. Eli Keshet is what Yigong Shi refers to as scientists devoted to basic research. China’s ability to improve basic scientific research is not a one-step solution and RunYoung’s vision is to build a bridge from reality to the future through our platform. Today, although we lack independent and transformable research, we are gradually transitioning from following to independent and innovative research by introducing basic research from the best international scientists and learning from their research ideas. Accordingly, RunYoung invests in at least 3-5 overseas basic research projects every year hoping to contribute to China’s current critical shortage of basic research. At the same time, we believe that support for such a group of dedicated and accomplished scientists, like planting saplings, will eventually bear the most fruitful results.

The post Breaking News | Eli Keshet, RunYoung’s Overseas Expert, Receives Israel’s Highest National Award for Life Science Research appeared first on RunYoung.

The Fund has an extensive network of strategic partnerships that its portfolio companies can leverage in order to penetrate the Chinese market. These include several top Chinese pharmacological and medical device companies, such as Sinopharm, Shanghai Pharma, and Kangji Medical, as well as leading Technology Transfer Organizations in Israel such as Yissum, Mor and Sheba.

The Fund also announced a new strategic partnership with CW Data to create a one-stop big data solution for the healthcare sector. CW Data is a joint venture between China Electronics Data Service Co., Ltd. (CECD) and WuXi AppTec, a leading life sciences technology platform, with 10,000 employees and operations in both China, United States, Europe, and Asia. RunYoung and CW Data will pool resources and explore a flexible cooperation model to streamline the introduction of cutting-edge technologies and medical treatments to China.

“Israel plays a pivotal role in global life sciences innovation” said Roger Lu, Founder & Chairman of the RunYoung Technology Transfer Center fund. “Our new strategic partnerships, including with CW Data and others, will facilitate the introduction, incubation, and commercialization of these technologies in China, which will ultimately benefit Chinese patients.”

RunYoung has already invested in three Israeli life sciences companies and several research projects originated at various Technology Transfer Offices. The Fund boasts both Israeli and Chinese advisory consulting teams, including a Nobel Prize winner, scientists, physicians and key thought leaders from leading medical and pharma companies and the CFDA. The Fund is managed in Israel by Dr. Benny Zeevi a veteran of the Israeli life sciences industry.

“Israel is a tiny market with a world-leading innovation ecosystem, while China is a massive market in need of innovation,” said Dr. Benny Zeevi. “With a fantastic team in place capable of identifying the most cutting-edge life science technologies early, RunYoung will be a bridge that will connect Israeli startups with the ever-growing Chinese market.”

About RunYoung

RunYoung is an early-stage venture capital firm investing in Israeli life science companies. It has strategic partnerships with leading pharmacological, medical device companies, and TTOs in China and Israel. The Fund boasts both Israeli and Chinese advisory consulting teams, including Nobel Prize winners, scientists, physicians and key thought leaders from leading medical and pharma companies and the CFDA. Read more about RunYoung here: https://runyoung.tech/en/

The post RunYoung Launches with $50M Life Sciences Fund & Strategic Partnerships Aimed at Bringing Israeli Tech to China appeared first on RunYoung.

Main product (technology) :

1. Multi-gene angiogenic growth vectors/grafts (MGAs) for peripheral arterial disease MGAs are formed using endothelial cells activated by the Ang-1 gene in combination with smooth muscle cells activated by the VEGF gene.
2. Multigene grafts (MGG) for dialysis access. MGG is formed by grafting endothelial cells + polymers activated by the fibulin-5 gene.

The post Vessl appeared first on RunYoung.

At the signing ceremony, four Sino-Israeli cooperative innovation and entrepreneurship platforms were unveiled including the Changzhou West Tai Lake Medical Technology International Innovation Center, the Life and Health Technology Research Center of Jiangsu Sino-Israeli Industrial Technology Research Institute, the Changzhou RunYoung Technology Transfer Center and the Jiangsu West Tai Lake Sino-Israeli Biomedical Research Institute.

Centralized Contract Settlement

The BRAINQ electroencephalography rehabilitation system, the VESSL vascular regeneration therapy, the LIFT acute respiratory distress syndrome drug delivery device and an age-related macular degeneration (AMD) therapeutic drug were the four Sino-Israeli technology transfer cooperation projects signed at the event. Bairen Medical Animal Source Implant Medical Devices, Jitai Technology Artificial Total Knee Joint Implant, Jieduo Medical Artificial Intelligence Technology Customized Osteotomy Guides and the Aose medical device testing laboratory are four key medical device projects signed at the event. In addition, the Changchuang Investment Innovation and Entrepreneurship Service Platform West Tai Lake Center signed a contract and settled in West Tai Lake Park. After the signing ceremony there were roadshow presentations done for four projects: BRAINQ, VESSL, LIFT and the AMD project. The event was capped off with a lively panel discussion.

The formal unveiling and signing of this series of innovation platforms and projects represented by the Sino-Israeli West Tai Lake Life and Health Technology Research Center and the West Tai Lake International Innovation Center for Medical Science and Technology is a new beginning for Sino-Israeli cooperation. This day marks the beginning for new breakthroughs, the acceleration of imported technologies, the construction of an innovation ecosystem, the strengthening of international cooperation, the promotion of the integrated development of health manufacturing and health services, and the creation of a new growth area for the development of the West Taihu Lake health industry.

July 10th, 2020

The post Held a Signing Ceremony for West Tai Lake Medical Innovation Projects from Sino-Israeli Cooperation. appeared first on RunYoung.

The post Runyoung Signed Key Agreements with Four of Israel’s Top Research Institutions appeared first on RunYoung.

The forum was hosted by the People’s Government of Changzhou and organized by the People’s Government of Wujin District of Changzhou, Changzhou West Taihu Lake Science and Technology Industrial Park, Changzhou-Israel Innovation Park, ECM MEDICAL, and Changzhou Runyoung Technology Transfer Center. The Central Biotechnology and Pharmacy Working Committee of CPWDP was the co-organizer and honored guests included Aaron Ciechanover, an Israeli nobel prize winner, Lianghua Jiang, Director of Chinese Academy of Sciences Shanghai Institute of Materia Medica (SIMM), Jian Ding, academician of the Chinese Academy of Sciences and the Chinese Academy of Engineering and other esteemed scientists. There were more than 200 attendees including experts and scholars, representatives of government agencies and key enterprises including high-tech medical enterprises, well-known investment institutions, medical institutions, universities and research institutes from China and Israel.

This Forum was one of the key activities of the 14th China Changzhou Advanced Manufacturing Technology Achievements Exhibition and Fair under the “Belt and Road” initiative and the “China-Israel Innovation Cooperation Action Plan (2018-2021)”. It was a basis for discussion for China and Israel, with a focus on medical industry trends and groundbreaking technologies and it provided a dialogue, exchange and collaboration platform for government, enterprises, experts from the field of medical technology innovation and development.

With the theme of “New Technology, New Health, New Future”, the forum included five on-site signings of innovative projects in the medical industry, six keynote speeches by top medical experts from China and Israel, two roundtable dialogues on medical technology and seventeen roadshow presentations of Israeli medical innovation projects.

May 20th, 2019

The post Runyoung hosted the 2nd Sino-Israeli Medical Technology Industry Summit Forum Together with Changzhou Municipal People’s Government appeared first on RunYoung.